CoChat

Investigating the neuronal role of the proteasomal ATPase subunit gene PSMC5 in neurodevelopmental proteasomopathies

Open access
Küry, Sébastien, Stanton, Janelle E., van Woerden, Geeske M., Bosc-Rosati, Amélie, Hsieh, Tzung-Chien, Bray, Lise, Oloudé, Marielle, Rosenfelt, Cory, Scott-Boyer, Marie Pier, Most, Victoria, Wang, Tianyun, Papendorf, Jonas J., de Konink, Charlotte, Deb, Wallid, Vignard, Virginie, Studencka-Turski, Maja, Besnard, Thomas, Hajdukowicz, Anna M., Thiel, Franziska G., Wolfgramm, Sophie, Florenceau, Laëtitia, Cuinat, Silvestre, Marsac, Sylvain, Verrès, Yann, Dangoumau, Audrey, Poirier, Léa, Wentzensen, Ingrid M., Tuttle, Annabelle, Forster, Cara, Striesow, Johanna, Golnik, Richard, Ortiz, Damara, Jenkins, Laura, Rosenfeld, Jill A., Ziegler, Alban, Houdayer, Clara, Bonneau, Dominique, Torti, Erin, Begtrup, Amber, Monaghan, Kristin G., Mullegama, Sureni V., Volker-Touw, Catharina M. L. Nienke, van Gassen, Koen L. I., Oegema, Renske, de Pagter, Mirjam S., Steindl, Katharina, Rauch, Anita, Ivanovski, Ivan, McDonald, Kimberly, Boothe, Emily, Dauber, Andrew, Baker, Janice, Fabie, Noelle Andrea V., Bernier, Raphael A., Turner, Tychele N., Srivastava, Siddharth, Dies, Kira A., Swanson, Lindsay C., Costin, Carrie, Abdulrazak, Alali, Jobling, Rebekah K., Pappas, John, Rabin, Rachel, Niyazov, Dmitriy, Chun-Hui Tsai, Anne, Kovak, Karen, Beck, David B., Malicdan, May Christine V., Adams, David R., Wolfe, Lynne, Ganetzky, Rebecca D., Muraresku, Colleen C., Babikyan, Davit, Sedláček, Zdeněk, Hančárová, Miroslava, Timberlake, Andrew T., Saif, Hind Al, Nestler, Berkley, King, Kayla, Hajianpour, MJ, Costain, Gregory, Prendergast, D’Arcy, Li, Chumei, Geneviève, David, Vitobello, Antonio, Sorlin, Arthur, Philippe, Christophe, Harel, Tamar, Toker, Ori, Sabir, Ataf, Lim, Derek, Hamilton, Mark J., Bryson, Lisa J., Cleary, Elaine, Weber, Sacha, Hoffman, Trevor L., Cueto-González, Anna M., Tizzano, Eduardo F., Gómez-Andrés, David, Codina-Solà, Marta, Ververi, Athina, Pavlidou, Efterpi, Lambropoulos, Alexandros, Garganis, Kyriakos, Rio, Marlène, Levy, Jonathan, Langas, Sarah J., McRae, Anne M., Lessard, Mathieu K., D’Agostino, Maria Daniela, De Bie, Isabelle, Wegler, Meret, Abou Jamra, Rami, Kamphausen, Susanne B., Bothe, Viktoria, Potocki, Lorraine, Olinger, Eric, Sznajer, Yves, Wiame, Elsa, Thompson, Michelle L., Schroeder, Molly C., Gooch, Catherine, Smith, Raphael A., Pandya, Arti, Busch, Larissa M., Völker, Uwe, Hammer, Elke, Wende, Kristian, Cogné, Benjamin, Isidor, Bertrand, Meiler, Jens, Ripoll, Clémentine, Bigou, Stéphanie, Laumonnier, Frédéric, Hildebrand, Peter W., Eichler, Evan E., McWalter, Kirsty, Krawitz, Peter M., Roux-Dalvai, Florence, Elgersma, Ype, Marcoux, Julien, Bousquet, Marie-Pierre, Droit, Arnaud, Poschmann, Jeremie, Grabrucker, Andreas M., Bolduc, Francois V., Bézieau, Stéphane, Ebstein, Frédéric, Krüger, Elke · 2025 · Nature Communications

The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index; 20 of the 26 sources its claims cite were checked for support.

Abstract

Neurodevelopmental proteasomopathies are a group of disorders caused by variants in proteasome subunit genes, that disrupt protein homeostasis and brain development through poorly characterized mechanisms. Here, we report 26 distinct variants in PSMC5 , encoding the AAA⁺ ATPase subunit PSMC5/RPT6, in individuals with syndromic neurodevelopmental conditions. Combining genetic, multi-omics and biochemical approaches across cellular models and Drosophila , we unveil the essential role of proteasomes in sustaining key cellular processes. Loss of PSMC5/RPT6 function impairs proteasome activity, leading to protein aggregation, disruption of mitochondrial homeostasis, and dysregulation of lipid metabolism and immune signaling. It also compromises synaptic balance, neuritogenesis, and neural progenitor cell stemness, causing deficits in higher-order functions, including learning and locomotion. Pharmacological targeting of integrated stress response kinases reveals a mechanistic link between proteotoxic stress and spontaneous type I interferon activation. These findings expand our understanding of proteasome-dependent quality control in neurodevelopment and suggest potential therapeutic strategies for neurodevelopmental proteasomopathies.

Overview

CoChat Summary

TL;DR

This study identifies 26 distinct PSMC5 variants in 44 individuals with syndromic neurodevelopmental conditions and shows that loss of PSMC5/RPT6 function impairs proteasome activity, proteostasis, mitochondrial and lipid homeostasis, immune signaling, synaptic balance, and neural progenitor differentiation. Multi-model functional work links proteotoxic stress to type I interferon activation via the integrated stress response and suggests PKR, GCN2, and JAK inhibition as potential therapeutic targets.

Key findings

  • In 44 affected individuals, 26 distinct PSMC5 variants were found, mostly missense (19/26) and within the AAA-ATPase domain (16/26); 33 cases were de novo, and ACMG/AMP simulation suggested pathogenicity for 25/26 variants. Recurrent variants included c.959C>G p.(Pro320Arg) in 6/44 and c.973C>T p.(Arg325Trp) in 9/44.
  • Clinical features included global developmental delay in 42/44 (95%), speech absence/delay in 36/39 (92%), intellectual disability in 26/32 (81%), motor delay/impairment in 32/41 (78%), abnormal behavior in 30/39 (77%), seizures in 14/43 (33%), and abnormal facial shape in 32/40 (80%).
  • Psmc5 knockdown in rat hippocampal neurons reduced PSMC5 protein to 12.71% ± 1.61% versus 100% ± 36.76% in controls, increased ubiquitin accumulation, and reduced vGlut⁺ excitatory puncta (control 1.2 ± 0.1 vs KD 0.8 ± 0.1; p = 0.0045) while vGat⁺ puncta remained stable. Drosophila Rpt6 knockdown impaired reversal learning (KD 1.5 ± 2 vs WT 43 ± 1.9; p < 0.0001) and caused age-dependent climbing decline.
  • Patient T cells showed increased aggresome formation (MFI 64.53 ± 11.77 vs control 34.58 ± 2.148; p = 0.0159), high-molecular-weight ubiquitin accumulation, altered mitochondrial and lipid metabolism, and a type I IFN signature; PKR inhibitor C16, STING inhibitor H-151, GCN2 inhibitor A92, and JAK inhibitor baricitinib reduced IFN scores, whereas IRE1 inhibitor 4µ8C did not. iPSC-derived NPCs with p.(Arg325Trp) had 10% fewer SOX2⁺ and 7% fewer Nestin⁺ cells than wild-type.

Methods

  • Genetic and clinical study of 44 affected individuals and available relatives, with genome/exome sequencing, clinical phenotyping, 3D structural mapping of variants, and GestaltMatcher facial analysis.
  • Functional models included Drosophila Rpt6 knockdown for olfactory, reversal, and climbing assays; rat hippocampal neuron Psmc5 shRNA knockdown; mouse hippocampal neuron overexpression of selected PSMC5 variants; patient-derived T cells for proteomics, lipidomics, Native-PAGE, flow cytometry, and IFN assays; and CRISPR/Cas9-edited iPSCs differentiated into germ layers and neural progenitor cells.
  • Analyses used t-tests, Mann-Whitney U tests, one-way ANOVA with Tukey or Dunnett’s post hoc tests, Wilcoxon tests, mass spectrometry, transcriptomics, and lipidomics, with statistical thresholds reported per experiment.

Limitations

  • The paper states that no statistical method was used to predetermine sample size, no data were excluded except proteomics outliers with high missing values, experiments were not randomized, and investigators were not blinded to allocation during experiments and outcome assessment.
  • The authors note limited follow-up on clinical progression, difficulty drawing a clear genotype-phenotype correlation because of important phenotypic variability, and in vivo/in vitro discrepancies for some variants.
  • Evident from the text: functional assays often used small numbers of subjects, images, neurons, or biological replicates, and not all 26 variants were tested in every cellular or animal assay.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-025-65556-8

Cites

70 of 71 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Structural mapping of PSMC5 variants highlights clustering within the AAA⁺ ATPase domain. a Schematic of the PSMC5/RPT6 protein showing 26 variants identified in NDD patients. Approximately half cluster within three hotspot regions of the AAA⁺ ATPase domain. Missense variants are shown in blue, frameshift/indels in red, and splice site variants in purple. Numbers indicate the count of unrelated individuals carrying each variant. b Structural localization of PSMC5 variants within the 26S proteasome (based on PDB: 6MSK). Variants (spheres) are primarily situated in the lower ATPase domain of RPT6. Portions of the complex were hidden to enhance visibility; RPT6 is shown in cartoon representation.
Fig. 1 Structural mapping of PSMC5 variants highlights clustering within the AAA⁺ ATPase domain. a Schematic of the PSMC5/RPT6 protein showing 26 variants identified in NDD patients. Approximately half cluster within three hotspot regions of the AAA⁺ ATPase domain. Missense variants are shown in blue, frameshift/indels in red, and splice site variants in purple. Numbers indicate the count of unrelated individuals carrying each variant. b Structural localization of PSMC5 variants within the 26S proteasome (based on PDB: 6MSK). Variants (spheres) are primarily situated in the lower ATPase domain of RPT6. Portions of the complex were hidden to enhance visibility; RPT6 is shown in cartoon representation.CC BY · PubMed Central
Fig. 2 Clinical features associated with PSMC5 variants. a Radar chart summarizing the most frequent clinical findings in the cohort. b Pairwise rank matrix and hierarchical clustering of 15 PSMC5 subjects (avatars shown). A red box highlights individuals with at least one match ranked below 50, indicating shared facial features. c Visualization of HPO-based phenotypic categories across affected individuals. Circle size reflects the number of phenotypes assessed per subject; color indicates the proportion calculated (dark blue: low, red: high). Categories are ranked by average prevalence, with nervous system and head/neck anomalies most frequently observed.
Fig. 2 Clinical features associated with PSMC5 variants. a Radar chart summarizing the most frequent clinical findings in the cohort. b Pairwise rank matrix and hierarchical clustering of 15 PSMC5 subjects (avatars shown). A red box highlights individuals with at least one match ranked below 50, indicating shared facial features. c Visualization of HPO-based phenotypic categories across affected individuals. Circle size reflects the number of phenotypes assessed per subject; color indicates the proportion calculated (dark blue: low, red: high). Categories are ranked by average prevalence, with nervous system and head/neck anomalies most frequently observed.CC BY · PubMed Central
Fig. 3 Psmc5 suppression impairs reversal learning in flies and alters synaptic balance in rat hippocampal neurons. All data are presented as mean±SEM. a–c Pan-neuronal KD of Rpt6 (PSMC5) in Drosophila had no effect on normal olfactory learning (two-sided Student’s t-test; wild-type WT: 78 ± 2.9; KD(Elav:Rpt634712): 82 ± 1.7; p = 0.3059; n = 4 biological replicates of PI), but significantly impaired reversal learning (one-way ANOVA with Tukey post hoc; WT: 43 ± 1.9; WT:Elav: 40 ± 1.7; WT:Rpt634712: 42 ± 3; KD(Elav:Rpt634712): 1.5 ± 2; p < 0.0001, n = 4 PI), with age-persistent deficits. ***p < 0.001; ****p < 0.0001. d–j Climbing activity declined in Rpt6 KD flies over time: at 1–3 days (two-sided t-test; WT: 81.5% ± 5.8%; KD: 42.9% ± 4.4%; p < 0.0001; n = 10 biological replicates); at 6–8 days (two-sided t-test; WT: 81.5% ± 5.5%; KD: 43.1% ± 9.1%; p = 0.0021; n = 10 biological replicates); at 22–24 days (t two-sided t-test: 82.7% ± 2.7%; KD: 12.7%±2.5%; p < 0.0001; n = 10 biological replicates). WT flies maintained performance across all ages. **p < 0.01; ***p < 0.001. k–n Primary rat hippocampal neurons infected with lentiviral particles (GFP + scrambled or Psmc5-KD shRNA) showed: reduced PSMC5 protein in GFP positive (+) Psmc5 KD neurons compared to scrambled controls (two-sided Mann Whitney test; control: 100% ± 36.76%; KD: 12.71% ± 1.61%; p = 0.0002, n = 10 images analyzed per condition); and increased ubiquitin accumulation (two-sided Mann Whitney test; control: 2.8 × 106 ± 1.3 × 105; KD: 4.8 × 106 ± 5.6 × 105; p = 0.0022, n = 6). Scale bar = 20 μm. o, p No significant difference in dendritic branching was observed at DIV14 between Psmc5 KD and control neurons (two-sided Mann-Whitney test). The two groups exhibited comparable numbers of primary dendrites (control: 3.67 ± 0.33; Psmc5 KD: 3.83 ± 0.31; p = 0.749), secondary dendrites (control: 13.00 ± 1.37; KD: 13.17 ± 2.10; p = 0.873) and tertiary dendrites (control: 17.50 ± 6.69; KD: 18.33 ± 1.73; p = 0.575). n = 6 neurons per condition. MAP2 staining of infected neurons is shown in red. Scale bar: 20 μm. q, r Synaptic analysis revealed: Reduced vGlut⁺ excitatory puncta (two-sided Mann Whitney test; control: 1.2 ± 0.1; KD: 0.8 ± 0.1; p = 0.0045; n = 5) and stable vGat⁺ (two-sided Mann Whitney test; control: 0.8 ± 0.08; KD: 1.0 ± 0.2; p = 0.2988; n = 5) in KD neurons. s, t Decreased vGlut⁺ (filled arrows) and stable vGat⁺ (open arrows) signals in KD vs. control neurons. *p < 0.05; **p < 0.01. Scale bar = 5 μm.
Fig. 3 Psmc5 suppression impairs reversal learning in flies and alters synaptic balance in rat hippocampal neurons. All data are presented as mean±SEM. a–c Pan-neuronal KD of Rpt6 (PSMC5) in Drosophila had no effect on normal olfactory learning (two-sided Student’s t-test; wild-type WT: 78 ± 2.9; KD(Elav:Rpt634712): 82 ± 1.7; p = 0.3059; n = 4 biological replicates of PI), but significantly impaired reversal learning (one-way ANOVA with Tukey post hoc; WT: 43 ± 1.9; WT:Elav: 40 ± 1.7; WT:Rpt634712: 42 ± 3; KD(Elav:Rpt634712): 1.5 ± 2; p < 0.0001, n = 4 PI), with age-persistent deficits. ***p < 0.001; ****p < 0.0001. d–j Climbing activity declined in Rpt6 KD flies over time: at 1–3 days (two-sided t-test; WT: 81.5% ± 5.8%; KD: 42.9% ± 4.4%; p < 0.0001; n = 10 biological replicates); at 6–8 days (two-sided t-test; WT: 81.5% ± 5.5%; KD: 43.1% ± 9.1%; p = 0.0021; n = 10 biological replicates); at 22–24 days (t two-sided t-test: 82.7% ± 2.7%; KD: 12.7%±2.5%; p < 0.0001; n = 10 biological replicates). WT flies maintained performance across all ages. **p < 0.01; ***p < 0.001. k–n Primary rat hippocampal neurons infected with lentiviral particles (GFP + scrambled or Psmc5-KD shRNA) showed: reduced PSMC5 protein in GFP positive (+) Psmc5 KD neurons compared to scrambled controls (two-sided Mann Whitney test; control: 100% ± 36.76%; KD: 12.71% ± 1.61%; p = 0.0002, n = 10 images analyzed per condition); and increased ubiquitin accumulation (two-sided Mann Whitney test; control: 2.8 × 106 ± 1.3 × 105; KD: 4.8 × 106 ± 5.6 × 105; p = 0.0022, n = 6). Scale bar = 20 μm. o, p No significant difference in dendritic branching was observed at DIV14 between Psmc5 KD and control neurons (two-sided Mann-Whitney test). The two groups exhibited comparable numbers of primary dendrites (control: 3.67 ± 0.33; Psmc5 KD: 3.83 ± 0.31; p = 0.749), secondary dendrites (control: 13.00 ± 1.37; KD: 13.17 ± 2.10; p = 0.873) and tertiary dendrites (control: 17.50 ± 6.69; KD: 18.33 ± 1.73; p = 0.575). n = 6 neurons per condition. MAP2 staining of infected neurons is shown in red. Scale bar: 20 μm. q, r Synaptic analysis revealed: Reduced vGlut⁺ excitatory puncta (two-sided Mann Whitney test; control: 1.2 ± 0.1; KD: 0.8 ± 0.1; p = 0.0045; n = 5) and stable vGat⁺ (two-sided Mann Whitney test; control: 0.8 ± 0.08; KD: 1.0 ± 0.2; p = 0.2988; n = 5) in KD neurons. s, t Decreased vGlut⁺ (filled arrows) and stable vGat⁺ (open arrows) signals in KD vs. control neurons. *p < 0.05; **p < 0.01. Scale bar = 5 μm.CC BY · PubMed Central
Fig. 4 PSMC5 overexpression alters neuronal morphology. a Representative images of primary hippocampal neurons transfected with empty vector (EV) control, wild-type PSMC5 (PSMC5-WT), or PSMC5 variants. Transfected cells are labeled in red (tdTomato); MAP2 staining (blue) marks neuronal morphology. b Quantification of total neurite length shows: (i) a significant increase with PSMC5-WT (1.29 ± 0.08) compared to EV (1 ± 0.04; one-way ANOVA, F = 3.296, p = 0.0014; EV vs. PSMC5-WT, p = 0.0046, Dunnett’s multiple comparisons test); (ii) Comparable effects for variants p.(Arg201Trp), p.(Pro320His), and p.(Arg325Trp) vs. PSMC5-WT: 1.18 ± 0.10, p = 0.8; 1.19 ± 0.09, p = 0.8; and 1.14 ± 0.09, p = 0.5; respectively; and (iii) a significant decrease for variants p.(Ala202Val), p.(Thr207Met), p.(Pro320Arg), and p.(Ala324Lys360del) compared to PSMC5-WT: 0.93 ± 0.07, p = 0.0031; 1.02 ± 0.06, p = 0.02; 1.19 ± 0.09; p = 0.006; and 1.00 ± 0.07, p = 0.03, respectively, with effects indistinguishable from EV (p = 0.4, p = 0.9, p = 0.9, and p = 0.9, respectively). c Sholl analysis revealed no significant differences in dendritic arborization across conditions (one-way ANOVA, F = 2.179, p = 0.03; EV vs. PSMC5-WT: 1.12 ± 0.09, p = 0.9; PSMC5-WT vs. p.(Arg201Trp): 1.16 ± 0.14, p = 0.9; PSMC5-WT vs. p.(Ala202Val): 1.00 ± 0.12, p = 0.9; PSMC5-WT vs. p.(Thr207Met), 0.94 ± 0.06, p = 0.6; PSMC5-WT vs. p.(Pro320His), 1.36 ± 0.14, p = 0.3; PSMC5-WT vs. p.(Pro320Arg), 0.94 ± 0.06, p = 0.9; PSMC5-WT vs. p.(Arg 325Trp), 1.13 ± 0.09, p = 0.9; PSMC5-WT vs. p.(Ala324Lys360del), 1.03 ± 0.07 p = 0.9; Dunnet’s multiple comparison test). Error bars indicate SEM; n (number of neurons traced): EV = 40, PSMC5-WT = 30, p.(Arg201Trp) = 18 p.(Ala202Val) = 20, p.(Thr207Met) = 27, p.(Pro320Arg) = 29, p.(Pro320Arg) = 19, p.(Arg325Trp) = 20 and p.(Ala324Lys360del) = 20. *p < 0.05; **p < 0.01. Scale bar: 100 µm.
Fig. 4 PSMC5 overexpression alters neuronal morphology. a Representative images of primary hippocampal neurons transfected with empty vector (EV) control, wild-type PSMC5 (PSMC5-WT), or PSMC5 variants. Transfected cells are labeled in red (tdTomato); MAP2 staining (blue) marks neuronal morphology. b Quantification of total neurite length shows: (i) a significant increase with PSMC5-WT (1.29 ± 0.08) compared to EV (1 ± 0.04; one-way ANOVA, F = 3.296, p = 0.0014; EV vs. PSMC5-WT, p = 0.0046, Dunnett’s multiple comparisons test); (ii) Comparable effects for variants p.(Arg201Trp), p.(Pro320His), and p.(Arg325Trp) vs. PSMC5-WT: 1.18 ± 0.10, p = 0.8; 1.19 ± 0.09, p = 0.8; and 1.14 ± 0.09, p = 0.5; respectively; and (iii) a significant decrease for variants p.(Ala202Val), p.(Thr207Met), p.(Pro320Arg), and p.(Ala324Lys360del) compared to PSMC5-WT: 0.93 ± 0.07, p = 0.0031; 1.02 ± 0.06, p = 0.02; 1.19 ± 0.09; p = 0.006; and 1.00 ± 0.07, p = 0.03, respectively, with effects indistinguishable from EV (p = 0.4, p = 0.9, p = 0.9, and p = 0.9, respectively). c Sholl analysis revealed no significant differences in dendritic arborization across conditions (one-way ANOVA, F = 2.179, p = 0.03; EV vs. PSMC5-WT: 1.12 ± 0.09, p = 0.9; PSMC5-WT vs. p.(Arg201Trp): 1.16 ± 0.14, p = 0.9; PSMC5-WT vs. p.(Ala202Val): 1.00 ± 0.12, p = 0.9; PSMC5-WT vs. p.(Thr207Met), 0.94 ± 0.06, p = 0.6; PSMC5-WT vs. p.(Pro320His), 1.36 ± 0.14, p = 0.3; PSMC5-WT vs. p.(Pro320Arg), 0.94 ± 0.06, p = 0.9; PSMC5-WT vs. p.(Arg 325Trp), 1.13 ± 0.09, p = 0.9; PSMC5-WT vs. p.(Ala324Lys360del), 1.03 ± 0.07 p = 0.9; Dunnet’s multiple comparison test). Error bars indicate SEM; n (number of neurons traced): EV = 40, PSMC5-WT = 30, p.(Arg201Trp) = 18 p.(Ala202Val) = 20, p.(Thr207Met) = 27, p.(Pro320Arg) = 29, p.(Pro320Arg) = 19, p.(Arg325Trp) = 20 and p.(Ala324Lys360del) = 20. *p < 0.05; **p < 0.01. Scale bar: 100 µm.CC BY · PubMed Central
Fig. 5 Altered proteasome expression and activity in T cells from NDD subjects harboring PSMC5 variants. a Western blot analysis of T cells expanded from PBMCs of NDD subjects (S7, S14, S15, S25, S36), related controls (parents), and unrelated healthy donors. Lysates were probed with anti-PSMC5/RPT6 and GAPDH antibodies. Full-length PSMC5/RPT6 (~45 kDa; arrow) was detected in all samples. Additional lower molecular weight (LMM) bands (~30 kDa; brackets) were observed in S7, S14, S25, and S36, while S15 showed a distinct band (~40 kDa; asterisk). Lower panel: Densitometric quantification of full-length and LMM species normalized to GAPDH. Data are shown as mean±SD of biological replicates for controls (n = 9) and patients (n = 5); two-tailed Mann–Whitney U test (***p = 0.0007). b Native-PAGE analysis of resting T cells from NDD subjects (S7, S14, S15, S25, S36, S37; n = 6), related controls, and healthy donors. Non-denatured lysates were prepared with TSDG buffer and probed with anti-α6 and anti-PSMC5/RPT6 antibodies. Proteasome complexes (20S, 26S) were visualized by in-gel activity assay using the fluorogenic peptide Suc-LLVY-AMC. Lower panel: Quantification of LLVY-AMC fluorescence and α6/RPT6 signals in 30S/26S complexes, shown as fold change relative to controls (normalized to 1). Data represent mean±SD of biological replicates (n = 6); two-tailed Mann–Whitney U test (*p = 0.0476). c Bottom-up mass spectrometry (BU-MS) analysis of 20S-associated 19S subunits in immunopurified proteasomes from five patient and six control T cells (n = 11). Each point represents the intensity of an individual 19S subunit; statistical analysis by one-way ANOVA with repeated measures, Geisser–Greenhouse correction, and Šidák’s multiple comparison (***p < 0.001, **p < 0.01). Data are presented as mean values ± SD of biological replicates for controls (1.53 ± 0.5; n = 6) and patients (S15 1.47 ± 0.5; S14 1.29 ± 0.4; S25 1.14 ± 0.4; S36 1.22 ± 0.5; S37 0.85 ± 0.4; n = 5). d Individual 19S subunit intensities for subject S37 and matched controls from (c).
Fig. 5 Altered proteasome expression and activity in T cells from NDD subjects harboring PSMC5 variants. a Western blot analysis of T cells expanded from PBMCs of NDD subjects (S7, S14, S15, S25, S36), related controls (parents), and unrelated healthy donors. Lysates were probed with anti-PSMC5/RPT6 and GAPDH antibodies. Full-length PSMC5/RPT6 (~45 kDa; arrow) was detected in all samples. Additional lower molecular weight (LMM) bands (~30 kDa; brackets) were observed in S7, S14, S25, and S36, while S15 showed a distinct band (~40 kDa; asterisk). Lower panel: Densitometric quantification of full-length and LMM species normalized to GAPDH. Data are shown as mean±SD of biological replicates for controls (n = 9) and patients (n = 5); two-tailed Mann–Whitney U test (***p = 0.0007). b Native-PAGE analysis of resting T cells from NDD subjects (S7, S14, S15, S25, S36, S37; n = 6), related controls, and healthy donors. Non-denatured lysates were prepared with TSDG buffer and probed with anti-α6 and anti-PSMC5/RPT6 antibodies. Proteasome complexes (20S, 26S) were visualized by in-gel activity assay using the fluorogenic peptide Suc-LLVY-AMC. Lower panel: Quantification of LLVY-AMC fluorescence and α6/RPT6 signals in 30S/26S complexes, shown as fold change relative to controls (normalized to 1). Data represent mean±SD of biological replicates (n = 6); two-tailed Mann–Whitney U test (*p = 0.0476). c Bottom-up mass spectrometry (BU-MS) analysis of 20S-associated 19S subunits in immunopurified proteasomes from five patient and six control T cells (n = 11). Each point represents the intensity of an individual 19S subunit; statistical analysis by one-way ANOVA with repeated measures, Geisser–Greenhouse correction, and Šidák’s multiple comparison (***p < 0.001, **p < 0.01). Data are presented as mean values ± SD of biological replicates for controls (1.53 ± 0.5; n = 6) and patients (S15 1.47 ± 0.5; S14 1.29 ± 0.4; S25 1.14 ± 0.4; S36 1.22 ± 0.5; S37 0.85 ± 0.4; n = 5). d Individual 19S subunit intensities for subject S37 and matched controls from (c).CC BY · PubMed Central
Fig. 6 PSMC5 variants disrupt protein homeostasis in T cells. a T cells expanded from PBMCs of NDD subjects (S7, S14, S15, S25, S36; n = 5) were stained with 1 µM of the PROTEOSTAT® dye and analyzed by flow cytometry using the B3 (PerCP-Vio 700) channel. PROTEOSTAT® selectively intercalates into the cross-β structures of misfolded and aggregated proteins. All T cells harboring PSMC5 variants exhibited elevated aggresome formation, as indicated by increased PROTEOSTAT® fluorescence intensity. Left panel: representative histogram overlay comparing the six patient samples to a healthy control. Middle panel: mean fluorescence intensity (MFI) values of activity-based probe (ABP)-treated T cells are shown as mean ± SEM of biological replicates for patient (PSMC5 variant, 64.53 ± 11.77, n = 5) and control (34.58 ± 2.148, n = 5) groups. *p = 0.0159, two-tailed Mann–Whitney U test. Right panel: aggresome propensity factor (APF) calculated for each patient as the percentage difference in MFI between MG-132–treated and untreated cells, normalized to the MG-132–treated condition. b T cells from NDD subjects (S1, S7, S14, S15, S25, S36; n = 6), their relatives (father, mother and/or brother), and unrelated healthy donors (controls, n = 6) were subjected to RIPA-based protein extraction followed by SDS-PAGE and western blotting using antibodies against ubiquitin, β-actin, and GAPDH (sample processing controls). Right panel: densitometric quantification of ubiquitin normalized to β-actin. Data are presented as mean ± SD for control (n = 6) and patient (PSMC5 variant, n = 6) groups. **p = 0.0047, two-tailed Mann–Whitney U test.
Fig. 6 PSMC5 variants disrupt protein homeostasis in T cells. a T cells expanded from PBMCs of NDD subjects (S7, S14, S15, S25, S36; n = 5) were stained with 1 µM of the PROTEOSTAT® dye and analyzed by flow cytometry using the B3 (PerCP-Vio 700) channel. PROTEOSTAT® selectively intercalates into the cross-β structures of misfolded and aggregated proteins. All T cells harboring PSMC5 variants exhibited elevated aggresome formation, as indicated by increased PROTEOSTAT® fluorescence intensity. Left panel: representative histogram overlay comparing the six patient samples to a healthy control. Middle panel: mean fluorescence intensity (MFI) values of activity-based probe (ABP)-treated T cells are shown as mean ± SEM of biological replicates for patient (PSMC5 variant, 64.53 ± 11.77, n = 5) and control (34.58 ± 2.148, n = 5) groups. *p = 0.0159, two-tailed Mann–Whitney U test. Right panel: aggresome propensity factor (APF) calculated for each patient as the percentage difference in MFI between MG-132–treated and untreated cells, normalized to the MG-132–treated condition. b T cells from NDD subjects (S1, S7, S14, S15, S25, S36; n = 6), their relatives (father, mother and/or brother), and unrelated healthy donors (controls, n = 6) were subjected to RIPA-based protein extraction followed by SDS-PAGE and western blotting using antibodies against ubiquitin, β-actin, and GAPDH (sample processing controls). Right panel: densitometric quantification of ubiquitin normalized to β-actin. Data are presented as mean ± SD for control (n = 6) and patient (PSMC5 variant, n = 6) groups. **p = 0.0047, two-tailed Mann–Whitney U test.CC BY · PubMed Central
Fig. 7 PSMC5 variants impair mitochondrial homeostasis, ribosome biogenesis and lipid metabolism in T cells. a Volcano plot of differentially expressed proteins in T cells from five individuals (four samples: three separate samples for S14, S15, S25, plus pooled sample from S36 and S37) versus nine controls, identified by mass spectrometry (n = 13 samples; p ≤ 0.05; log₂FC ≥ 1 or ≤–1; Student’s t-test). Red and blue dots indicate enriched or depleted pathways; green dots highlight mitochondrial proteins (MitoCarta 3.0)69. b Proteomics: Network clustering and pathway analysis of dysregulated proteins (p ≤ 0.05; –2 ≤ FC ≤ 2; Student’s t-test) using GO, KEGG, and STRING databases in Cytoscape (STRING Homo sapiens background). c Untargeted lipidomics of T cells from patients (S1, S7, S14, S15, S23, S25, S37; n = 7) and matched controls (parents and/or siblings; n = 6) revealed distinct lipid profiles by PCA in positive and negative ion modes (patients: blue; controls: red). d Fold-change analysis of lipid classes showed significant alterations in patient T cells (*p < 0.05, **p < 0.01, ***p < 0.001; two-tailed Student’s t-test). e Mitophagy was assessed by flow cytometry in T cells from patients (S1, S7, S14, S15, S25, S36, S37) and healthy donors (related and unrelated) using Mtphagy dye (100 nM, overnight; B4 channel, PE-Vio 770). Percentages of mitophagy-positive cells were significantly increased in patients (**p = 0.002, two-tailed Mann-Whitney U test). Data are presented as the mean percentage of mitophagy-positive cells ±SEM of biological replicates for controls (90.09 ± 3.330, n = 7) and patients (70.29 ± 3.525, n = 7).
Fig. 7 PSMC5 variants impair mitochondrial homeostasis, ribosome biogenesis and lipid metabolism in T cells. a Volcano plot of differentially expressed proteins in T cells from five individuals (four samples: three separate samples for S14, S15, S25, plus pooled sample from S36 and S37) versus nine controls, identified by mass spectrometry (n = 13 samples; p ≤ 0.05; log₂FC ≥ 1 or ≤–1; Student’s t-test). Red and blue dots indicate enriched or depleted pathways; green dots highlight mitochondrial proteins (MitoCarta 3.0)69. b Proteomics: Network clustering and pathway analysis of dysregulated proteins (p ≤ 0.05; –2 ≤ FC ≤ 2; Student’s t-test) using GO, KEGG, and STRING databases in Cytoscape (STRING Homo sapiens background). c Untargeted lipidomics of T cells from patients (S1, S7, S14, S15, S23, S25, S37; n = 7) and matched controls (parents and/or siblings; n = 6) revealed distinct lipid profiles by PCA in positive and negative ion modes (patients: blue; controls: red). d Fold-change analysis of lipid classes showed significant alterations in patient T cells (*p < 0.05, **p < 0.01, ***p < 0.001; two-tailed Student’s t-test). e Mitophagy was assessed by flow cytometry in T cells from patients (S1, S7, S14, S15, S25, S36, S37) and healthy donors (related and unrelated) using Mtphagy dye (100 nM, overnight; B4 channel, PE-Vio 770). Percentages of mitophagy-positive cells were significantly increased in patients (**p = 0.002, two-tailed Mann-Whitney U test). Data are presented as the mean percentage of mitophagy-positive cells ±SEM of biological replicates for controls (90.09 ± 3.330, n = 7) and patients (70.29 ± 3.525, n = 7).CC BY · PubMed Central
Fig. 8 PSMC5 variants trigger a spontaneous type I IFN response and distinct immune signature in T cells. a Heatmap of immune-related gene expression in T cells from five NDD subjects (S1, S14, S15, S25, S36; n = 5) versus five healthy controls (probands’ fathers and unrelated donors; n = 5), profiled using NanoString nCounter® (700-gene panel)11. Forty genes were differentially expressed, predominantly upregulated type I interferon-stimulated genes (ISGs), including STAT1, STAT2, UBE2L6, and HERC5. b Volcano plot from 3′ digital gene expression profiling showing 507 upregulated and 452 downregulated genes in PSMC5 variant carriers versus controls (padj≤0.05). Red and blue dots indicate upregulated and downregulated genes, respectively. c RT-qPCR quantification of seven ISGs (IFIT1, IFI27, IFI44, IFI44L, ISG15, MX1, RSAD2) in T cells from six patients (n = 6; S1, S14, S15, S25, S36, S37), healthy donors (HD), and eight related controls (parents; n = 8). Data represent biological replicates and type I IFN scores were calculated as median fold-change relative to a calibrator (*p = 0.0043, two-tailed Mann-Whitney U test). d T cells from six patients (S1, S14, S15, S25, S36, S37) were treated for 8 h with DMSO (vehicle), 4µ8C (100 µM), C16 (3 µM), H-151 (2 µM), baricitinib (1 µM) or A92 (10 µM) prior to ISG quantification by RT-qPCR. Data represent biological replicates and IFN scores under each condition (*p = 0.0313, Wilcoxon test).
Fig. 8 PSMC5 variants trigger a spontaneous type I IFN response and distinct immune signature in T cells. a Heatmap of immune-related gene expression in T cells from five NDD subjects (S1, S14, S15, S25, S36; n = 5) versus five healthy controls (probands’ fathers and unrelated donors; n = 5), profiled using NanoString nCounter® (700-gene panel)11. Forty genes were differentially expressed, predominantly upregulated type I interferon-stimulated genes (ISGs), including STAT1, STAT2, UBE2L6, and HERC5. b Volcano plot from 3′ digital gene expression profiling showing 507 upregulated and 452 downregulated genes in PSMC5 variant carriers versus controls (padj≤0.05). Red and blue dots indicate upregulated and downregulated genes, respectively. c RT-qPCR quantification of seven ISGs (IFIT1, IFI27, IFI44, IFI44L, ISG15, MX1, RSAD2) in T cells from six patients (n = 6; S1, S14, S15, S25, S36, S37), healthy donors (HD), and eight related controls (parents; n = 8). Data represent biological replicates and type I IFN scores were calculated as median fold-change relative to a calibrator (*p = 0.0043, two-tailed Mann-Whitney U test). d T cells from six patients (S1, S14, S15, S25, S36, S37) were treated for 8 h with DMSO (vehicle), 4µ8C (100 µM), C16 (3 µM), H-151 (2 µM), baricitinib (1 µM) or A92 (10 µM) prior to ISG quantification by RT-qPCR. Data represent biological replicates and IFN scores under each condition (*p = 0.0313, Wilcoxon test).CC BY · PubMed Central
Fig. 9 PSMC5 variant c.973C>T p.(Arg325Trp) impairs iPSC differentiation into germ layers and neural progenitors. a Schematic of ASE9211 iPSC clones edited via CRISPR/Cas9 to introduce the heterozygous p.Arg325Trp variant. Wild-type clones (ASE9211, C10, B10, E5) and mutant clones (G1, G8, H1) were differentiated into day-7 germ layer (GL) cells and day-28 neural progenitor cells (NPCs). b RT-qPCR of lineage-specific markers in GL cells: ectoderm (SOX1, PAX6), mesoderm (HAND1, TBXT), and endoderm (FOXA2, SOX17), normalized to RPLP13 and expressed relative to wild-type clone C10. Data represent biological replicates from six independent experiments for mutant cells. For wild-type cells, sample sizes were n = 4 for HAND1, TBXT, FOXA2, and SOX17; n = 6 for PAX6; and n = 7 for SOX1 (two-tailed unpaired t-test). c Volcano plot of differentially expressed genes in ectodermal cells from wild-type and mutant clones (padj≤0.05): 23 upregulated (red), 14 downregulated (blue). d Cnetplot of gene set enrichment analysis showing upregulated genes (orange) and enriched pathways (purple), notably cholesterol and sterol metabolism. e Immunofluorescence of NPCs stained for nestin (green), SOX2 (red), and DAPI (blue), comparing wild-type (ASE9211, E5) and mutant (G1, G8) clones. Quantification of nestin⁺ (f) and SOX2⁺ (g) cells relative to DAPI⁺ nuclei in NPCs from wild-type and mutant clones (≥20 images per line analyzed using Fiji software; mean±SEM; ****p < 0.0001, two-tailed unpaired t-test).
Fig. 9 PSMC5 variant c.973C>T p.(Arg325Trp) impairs iPSC differentiation into germ layers and neural progenitors. a Schematic of ASE9211 iPSC clones edited via CRISPR/Cas9 to introduce the heterozygous p.Arg325Trp variant. Wild-type clones (ASE9211, C10, B10, E5) and mutant clones (G1, G8, H1) were differentiated into day-7 germ layer (GL) cells and day-28 neural progenitor cells (NPCs). b RT-qPCR of lineage-specific markers in GL cells: ectoderm (SOX1, PAX6), mesoderm (HAND1, TBXT), and endoderm (FOXA2, SOX17), normalized to RPLP13 and expressed relative to wild-type clone C10. Data represent biological replicates from six independent experiments for mutant cells. For wild-type cells, sample sizes were n = 4 for HAND1, TBXT, FOXA2, and SOX17; n = 6 for PAX6; and n = 7 for SOX1 (two-tailed unpaired t-test). c Volcano plot of differentially expressed genes in ectodermal cells from wild-type and mutant clones (padj≤0.05): 23 upregulated (red), 14 downregulated (blue). d Cnetplot of gene set enrichment analysis showing upregulated genes (orange) and enriched pathways (purple), notably cholesterol and sterol metabolism. e Immunofluorescence of NPCs stained for nestin (green), SOX2 (red), and DAPI (blue), comparing wild-type (ASE9211, E5) and mutant (G1, G8) clones. Quantification of nestin⁺ (f) and SOX2⁺ (g) cells relative to DAPI⁺ nuclei in NPCs from wild-type and mutant clones (≥20 images per line analyzed using Fiji software; mean±SEM; ****p < 0.0001, two-tailed unpaired t-test).CC BY · PubMed Central

Verification

Claims the paper makes

12 Valid · 0 Not valid · 3 Not checked · 98 Own results and interpretations

63 more claims

Create a free account to see all 113 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 23
  • Probably not a substantial claim. 25
  • Not yet classified. 1
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 71 references

Cited by

See all 3

Metadata

Authors
Küry, S., Stanton, J. E., van Woerden, G. M., Bosc-Rosati, A., Hsieh, T.-C., Bray, L., Oloudé, M., Rosenfelt, C., Scott-Boyer, M. P., Most, V., Wang, T., Papendorf, J. J., de Konink, C., Deb, W., Vignard, V., Studencka-Turski, M., Besnard, T., Hajdukowicz, A. M., Thiel, F. G., Wolfgramm, S., Florenceau, L., Cuinat, S., Marsac, S., Verrès, Y., Dangoumau, A., Poirier, L., Wentzensen, I. M., Tuttle, A., Forster, C., Striesow, J., Golnik, R., Ortiz, D., Jenkins, L., Rosenfeld, J. A., Ziegler, A., Houdayer, C., Bonneau, D., Torti, E., Begtrup, A., Monaghan, K. G., Mullegama, S. V., Volker-Touw, C. M. L. N., van Gassen, K. L. I., Oegema, R., de Pagter, M. S., Steindl, K., Rauch, A., Ivanovski, I., McDonald, K., Boothe, E., Dauber, A., Baker, J., Fabie, N. A. V., Bernier, R. A., Turner, T. N., Srivastava, S., Dies, K. A., Swanson, L. C., Costin, C., Abdulrazak, A., Jobling, R. K., Pappas, J., Rabin, R., Niyazov, D., Chun-Hui Tsai, A., Kovak, K., Beck, D. B., Malicdan, M. C. V., Adams, D. R., Wolfe, L., Ganetzky, R. D., Muraresku, C. C., Babikyan, D., Sedláček, Z., Hančárová, M., Timberlake, A. T., Saif, H. A., Nestler, B., King, K., Hajianpour, M., Costain, G., Prendergast, D., Li, C., Geneviève, D., Vitobello, A., Sorlin, A., Philippe, C., Harel, T., Toker, O., Sabir, A., Lim, D., Hamilton, M. J., Bryson, L. J., Cleary, E., Weber, S., Hoffman, T. L., Cueto-González, A. M., Tizzano, E. F., Gómez-Andrés, D., Codina-Solà, M., Ververi, A., Pavlidou, E., Lambropoulos, A., Garganis, K., Rio, M., Levy, J., Langas, S. J., McRae, A. M., Lessard, M. K., D’Agostino, M. D., De Bie, I., Wegler, M., Abou Jamra, R., Kamphausen, S. B., Bothe, V., Potocki, L., Olinger, E., Sznajer, Y., Wiame, E., Thompson, M. L., Schroeder, M. C., Gooch, C., Smith, R. A., Pandya, A., Busch, L. M., Völker, U., Hammer, E., Wende, K., Cogné, B., Isidor, B., Meiler, J., Ripoll, C., Bigou, S., Laumonnier, F., Hildebrand, P. W., Eichler, E. E., McWalter, K., Krawitz, P. M., Roux-Dalvai, F., Elgersma, Y., Marcoux, J., Bousquet, M.-P., Droit, A., Poschmann, J., Grabrucker, A. M., Bolduc, F. V., Bézieau, S., Ebstein, F., & Krüger, E.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • University of Limerick (IE)
  • Institut de Pharmacologie et de Biologie Structurale (FR)
  • University of Bonn (DE)
  • Inserm (FR)
  • University of Alberta (CA)
  • Leipzig University (DE)
  • Peking University (CN)
  • Universitätsmedizin Greifswald (DE)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Université de Tours (FR)
  • Loyola University Chicago (US)
  • Leibniz Institute for Plasma Science and Technology (DE)
  • University of Pittsburgh (US)
  • Baylor College of Medicine (US)
  • Centre Hospitalier Universitaire de Toulouse (FR)
  • Centre Hospitalier Universitaire d'Angers (FR)
  • Utrecht University (NL)
  • University of Zurich (CH)
  • University of Louisville (US)
  • University of Mississippi Medical Center (US)
  • Children's National (US)
  • Children's Minnesota (US)
  • University of Washington (US)
  • Washington University in St. Louis (US)
  • Boston Children's Hospital (US)
  • Akron Children's Hospital (US)
  • West Virginia University (US)
  • Hospital for Sick Children (CA)
  • NYU Langone Health (US)
  • New York University (US)
  • Duke University (US)
  • Oregon Health & Science University (US)
  • National Institutes of Health (US)
  • Children's Hospital of Philadelphia (US)
  • Center of Medical Genetics and Primary Health Care (AM)
  • Charles University (CZ)
  • Virginia Commonwealth University (US)
  • Albany Medical College (US)
  • University of Toronto (CA)
  • McMaster University (CA)
  • Hebrew University of Jerusalem (IL)
  • Birmingham Women’s and Children’s NHS Foundation Trust (GB)
  • Queen Elizabeth University Hospital (GB)
  • Western General Hospital (GB)
  • Sorbonne Université (FR)
  • Kaiser Permanente (US)
  • Vall d'Hebron Institut de Recerca (ES)
  • Papageorgiou General Hospital (GR)
  • University Hospital of Ioannina (GR)
  • St. Luke's Hospital (GR)
  • Hôpital Necker-Enfants Malades (FR)
  • Northwestern University (US)
  • Lurie Children's Hospital (US)
  • McGill University Health Centre (CA)
  • University Hospital Leipzig (DE)
  • University Hospital Magdeburg (DE)
  • Cliniques Universitaires Saint-Luc (BE)
  • University of North Carolina at Chapel Hill (US)
  • Vanderbilt University (US)
  • Humboldt-Universität zu Berlin (DE)
  • Howard Hughes Medical Institute (US)
  • Erasmus MC (NL)
  • Université Laval (CA)
Corresponding author
  • Küry, Sébastien
  • Ebstein, Frédéric
  • Krüger, Elke
ORCID
Venue
Nature Communications
Published
2025-11-26
Volume
16
Issue
1
Pages
10545-10545
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4416719051
Cited by
3
References
70
Citations by year
2026: 2 · 2025: 1
FWCI
0.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
  • University of Birmingham Research Portal (University of Birmingham) (acceptedVersion, other-oa)
  • HAL (submittedVersion, cc-by)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • U.S. Department of Health and Human Services (R01MH101221, K23NS119666)
  • European Commission (ANR-10-IAIHU-06, HICF-1009-003, HORIZON2020, 825575)
  • European Cooperation in Science and Technology (ProteoCure CA20113)
  • Deutsche Forschungsgemeinschaft (SPP2453, 825575, 3HP-HP-FPA ERN-01-2016/739516, CA20113, SPP 2453 KR1915/11-1, RTG PRO 2719)
  • Agence Nationale de la Recherche (ANR-10-IAIHU06, 10-IAIHU-06, ANR-21-CE17-0005, ANR-10, ANR-22-RAR4-0001)
  • Institut National de la Santé et de la Recherche Médicale (ANR-10-IAIHU-06)
  • National Natural Science Foundation of China (82201314)
  • AXA Research Fund
  • Bundesministerium für Bildung und Forschung (03Z22DN12)
  • Centre Hospitalier Universitaire de Nantes (PROG/09/72-03, RC22_0020)
  • National Institutes of Health (-0001, ANR-10-IAIHU-06)
  • Fundamental Research Funds for the Central Universities (BMU2022RCZX038)
  • National Institute of Mental Health (R01MH101221, R01MH126933)
  • National Institute of Neurological Disorders and Stroke (K23NS119666)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Keywords
Rpt6, proteasome, AAA+ ATPase, proteostasis, protein aggregation, mitochondrial homeostasis, lipid metabolism, immune signaling, synaptic function, neurite outgrowth, integrated stress response, type I interferon, proteotoxic stress, Drosophila model
MeSH terms
ATPases Associated with Diverse Cellular Activities, Adenosine Triphosphatases, Animals, Child, Drosophila melanogaster, Female, Humans, Male, Mitochondria, Neurons, Drosophila Proteins, Proteasome Endopeptidase Complex, Neurodevelopmental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Investigating the neuronal role of the proteasomal ATPase subunit gene PSMC5 in neurodevelopmental proteasomopathies. https://app.cochat.ai/papers/10.1038/s41467-025-65556-8
The paper
Küry, S., Stanton, J. E., van Woerden, G. M., Bosc-Rosati, A., Hsieh, T.-C., Bray, L., Oloudé, M., Rosenfelt, C., Scott-Boyer, M. P., Most, V., Wang, T., Papendorf, J. J., de Konink, C., Deb, W., Vignard, V., Studencka-Turski, M., Besnard, T., Hajdukowicz, A. M., Thiel, F. G., . . . Krüger, E. (2025). Investigating the neuronal role of the proteasomal ATPase subunit gene PSMC5 in neurodevelopmental proteasomopathies. Nature Communications. https://doi.org/10.1038/s41467-025-65556-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.